A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study

Arch Pathol Lab Med. 2003 Mar;127(3):283-8. doi: 10.5858/2003-127-0283-ALRSOI.

Abstract

Objective: To identify the sources of analytical variation for cyclosporine and tacrolimus in a 3-year longitudinal study.

Design: Two pools of whole blood were spiked with cyclosporine and tacrolimus, respectively. One aliquot of cyclosporine and 2 of the tacrolimus pool were distributed in the first and last mailing for years 1999 to 2001. For both drugs, the total variance for each method was partitioned into within- and between-laboratory components.

Setting: The A and C mailings of the 1999, 2000, and 2001 AACC/CAP [American Association for Clinical Chemistry/College of American Pathologists] Immunosuppressive Drugs (CS) Monitoring Survey.

Main outcome measures: For each drug, total variance was partitioned into specimen, mailing, year, and interlaboratory effects for each analytical method.

Participants: The 292 laboratories for cyclosporine and 177 laboratories for tacrolimus enrolled in the survey from 1999 to 2001.

Results: For both cyclosporine and tacrolimus, the major source of imprecision came from within-laboratory factors, which accounted for nearly 85% (range, 77% to 90%) of the total variance. For cyclosporine, the major component of within-laboratory variance was between-mailing, within-year effect, whereas for tacrolimus it was the between-year, within-laboratory variation.

Conclusion: The major source of long-term survey imprecision for cyclosporine and tacrolimus is within-laboratory factors. The finding that 85% of the total variance was due to within-laboratory variation is similar to other therapeutic drugs.

Publication types

  • Multicenter Study

MeSH terms

  • Analysis of Variance
  • Clinical Competence / standards
  • Clinical Laboratory Techniques* / methods
  • Clinical Laboratory Techniques* / standards
  • Clinical Laboratory Techniques* / statistics & numerical data
  • Cyclosporine / blood
  • Drug Monitoring* / methods
  • Drug Monitoring* / standards
  • Drug Monitoring* / statistics & numerical data
  • Humans
  • Immunosuppressive Agents / blood*
  • Longitudinal Studies
  • Quality Control
  • Reference Values
  • Sensitivity and Specificity
  • Tacrolimus / blood
  • United States

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Tacrolimus